Assessment of the Safety and Effectiveness of Combining Immune Checkpoint Inhibitors with Chemotherapy for Advanced Triple-Negative Breast Cancer: A Comprehensive Meta-Analysis

1

Triple-negative breast cancer (TNBC) is aggressive, accounting for 15%-20% of breast cancers, with poor prognosis and limited treatment options.
2

Immune checkpoint inhibitors (ICIs) combined with chemotherapy significantly improve overall survival and progression-free survival in advanced TNBC.
3

The objective response rate did not show significant improvement in PD-L1-negative or PD-L1-positive populations when using ICIs with chemotherapy.
4

Combination therapy with ICIs is associated with increased risks of all-grade and grade ≥3 adverse events, including immune-related adverse events.
5

Future research is needed for detailed stratification to guide individualized treatment in advanced TNBC due to current evidence limitations.

1